Bifemelane: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Bifemelane": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(No difference)

Latest revision as of 18:08, 18 August 2015

Bifemelane
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H23NO
Molar mass269.381 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Bifemelane

Articles

Most recent articles on Bifemelane

Most cited articles on Bifemelane

Review articles on Bifemelane

Articles on Bifemelane in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bifemelane

Images of Bifemelane

Photos of Bifemelane

Podcasts & MP3s on Bifemelane

Videos on Bifemelane

Evidence Based Medicine

Cochrane Collaboration on Bifemelane

Bandolier on Bifemelane

TRIP on Bifemelane

Clinical Trials

Ongoing Trials on Bifemelane at Clinical Trials.gov

Trial results on Bifemelane

Clinical Trials on Bifemelane at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bifemelane

NICE Guidance on Bifemelane

NHS PRODIGY Guidance

FDA on Bifemelane

CDC on Bifemelane

Books

Books on Bifemelane

News

Bifemelane in the news

Be alerted to news on Bifemelane

News trends on Bifemelane

Commentary

Blogs on Bifemelane

Definitions

Definitions of Bifemelane

Patient Resources / Community

Patient resources on Bifemelane

Discussion groups on Bifemelane

Patient Handouts on Bifemelane

Directions to Hospitals Treating Bifemelane

Risk calculators and risk factors for Bifemelane

Healthcare Provider Resources

Symptoms of Bifemelane

Causes & Risk Factors for Bifemelane

Diagnostic studies for Bifemelane

Treatment of Bifemelane

Continuing Medical Education (CME)

CME Programs on Bifemelane

International

Bifemelane en Espanol

Bifemelane en Francais

Business

Bifemelane in the Marketplace

Patents on Bifemelane

Experimental / Informatics

List of terms related to Bifemelane

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bifemelane (Alnert, Celeport) is a pharmaceutical drug used in the treatment of senile dementia in Japan.[1] It has nootropic, neuroprotective, and antidepressant effects, and acts through the cholinergic system in the brain.[2][3][4] Bifemelane is also useful for the treatment of glaucoma.[5]


References

  1. David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 0-412-46630-9.
  2. Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research. 24 (4): 409–14. doi:10.1016/0168-0102(95)01017-3. PMID 8861111.
  3. Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology. 72 (1): 57–65. doi:10.1254/jjp.72.57. PMID 8902600.
  4. Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology. 72 (6): 394–7. doi:10.1111/j.1600-0773.1993.tb01351.x. PMID 8361950.
  5. Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics. 18 (1): 106–13. doi:10.1016/S0149-2918(96)80183-4. PMID 8851457.


Template:Nootropics